The pre-receptor activation of glucocorticoid production in adipose tissue by NADPHdependent 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) has emerged as a potential mechanism in the pathogenesis of visceral obesity and metabolic syndrome.
INTRODUCTION
Visceral fat deposition is frequently associated with metabolic syndrome including visceral obesity, insulin resistance, hypertension and dyslipidemia (22, 13, 39). However, the underlying mechanisms of these metabolic perturbations are poorly understood.
Patients with glucocorticoid (GC) excess (Cushing's syndrome) promote visceral fat deposition and develop metabolic syndrome (21, 1). In adipose tissue, GCs promote lipolysis by stimulating two key enzymes, hormone sensitive lipase (HSL) and adipose triglyceride lipase (ATGL) to increase hydrolysis of triacylglycerol and release free fatty acids (FFA) into the circulation that is linked to hyperlipidemia and global insulin resistance (8, 24, 46). However, tissue-specific glucocorticoid availability is regulated by an intracellular endoplasmic reticulum (ER) lumen-resident enzyme, 11ß-hydroxysteroid dehydrogenase type 1 (11ß-HSD1) that converts inert cortisone (11-dehydrocorticosterone in rodents) to the active glucocorticoid receptor (GR)-ligand cortisol (corticosterone in rodents) and thereby amplifies intracellular GC reproduction, particularly in adipose tissues (7, 41, 23, 33) . Increased adipose GC activation by 11ß-HSD1 leads to visceral obesity and features of the metabolic syndrome (29). Pre-receptor amplification of GC production in adipose tissue by 11ß-HSD1 is thus an emerging etiology for the pathogenesis of metabolic syndrome.
The function of 11ß-HSD1 is closely dependent upon its ability to activate GCs in vivo, in which it exhibits bi-directional activity. This dual action is controlled by its cofactor (NADPH) that is provided by the enzyme hexose-6-phosphate dehydrogenase (H6PDH) (34, 32). H6PDH is a microsomal enzyme located in the lumen of the endoplasmic reticulum (ER) and principally expressed in insulin target tissues, such as liver and adipose tissues, sites of 11ß-HSD1 and GR expression (20, 30) . In the ER lumen, H6PDH can metabolize glucose-6-phosphate (G6P) and NADP to generate NADPH, which is utilized by 11ß-HSD1. Targeted deletion or mutation of H6PDH results in a switch in set-point of 11ß-HSD1 inactivating cortisol to cortisone and demonstrated the physiologically relevant of 11ß-HSD1 for H6PDH (6, 14) . We recently reported that tissue-specific elevation of 11ß-HSD1 in liver, visceral, and subcutaneous fat is associated with H6PDH expression in obese db/db diabetic mice (47). In human subcutaneous adipose cells, H6PDH mRNA level is elevated during the differentiation of adipocytes with stimulation of cortisol production by 11ß-HSD1 (5). Clinical observations also have shown higher H6PDH expression in patients with type 2 diabetes (T2DM) than normal controls in both visceral and subcutaneous fat, implicating H6PDH as a contributing factor in the pathogenesis of T2DM (45). However, the phenotypic consequence of increasing H6PDH expression exclusively in adipose tissue has not been explored.
To test the hypothesis that increasing the H6PDH expression exclusively in adipose tissue would induce 11ß -HSD1 driving local GC production and lead to adverse metabolic phenotypes, we created transgenic mice overexpressing H6PDH under the control of the enhancer-promoter region of the adipocyte fatty acid binding protein (aP2) gene (aP2/H6PDH mice). Here we show that aP2/H6PDH mice have increased adipose corticosterone production and lipolysis and exhibit the features of modest metabolic syndrome.
MATERIALS AND METHODS
Generation of transgenic aP2-H6PDH mice. The 5.4-kb alpha P2 promoter/enhancer was used to drive fat-specific expression of the mouse H6PDH transgene. The transgenic expression vector was constructed by subcloning 4.6 kb EcoRV-NotI fragment of mouse H6PDH cDNA into a eukaryotic expression vector under the αP2 promoter (obtained from Dr. Bruce Spiegelman). The fragment containing αP2 promoter, H6PD cDNA and polyadenylation signal was released by restriction enzyme digestion and fractionated through agarose gel electrophoresis. The purified DNA fragement was microinjected into nuclei of pronuclear embryos (C57black/6). Injected embryos were implanted to psudeopregnant fosters to complete the gestation and birth. The transgenic founders were identified by PCR. Two independent lines with H6PDH overexpression in adipose tissue were obtained.
Animal study and metabolic analysis. This study was approved by the Institutional Animal Care and Use Committee of the Charles Drew University. Animals were weaned at the age of 3 weeks and housed in isolated cages under a 12-h light/dark cycle. Transgenic αP2-H6PDH mice and their nontransgenic littermates were given a standard laboratory chow diet with water ad libitum, and body weights and food intake were recorded weekly.
Glucose tolerance (GTTs) and insulin tolerance (ITTs) tests were performed as previously described (29, 47). For the glucose tolerance (GTT), 1 g/kg glucose was used in mice after a 12-h fast. For the insulin tolerance test (ITT), animals were fasted for 8 h, and blood samples were drawn at indicated time points following insulin injection (0.75 U/kg, ip; Novolin R; Eli Lilly, Indianapolis, IN). Blood samples were collected between 0900 and 1000 and fat pads were weighed and frozen in liquid nitrogen, and stored at -80 ˚C until metabolic assays.
Biochemical Assays. Blood glucose levels were determined by the glucose oxidase method.
Commercially available kits were used to measure plasma corticosterone, insulin, and free fatty acid (FFA) levels (Abcam, UK).
Adipocyte morphometric evaluation and culture of primary adipose cells. Three mice per experimental group were analyzed, with three representative images per section were taken for epididymal fat pad sections per mouse. Adipose morphometry was visualized by H&E staining. Adipocyte size was determined using the NIH ImageJ software. To quantify cell number, adipocytes were isolated from mouse epididymal adipose pad by using 1 mg/ml collagenase type II (Sigma, St. Louis, MO) in KRBH buffer (Sigma K4002) with 1% fatty acid-free BSA at a ratio of 1.5 ml buffer for every 100 mg tissue as described previously (12, 11). After digestion, the mature adipocytes were separated from the stromal vascular cells containing preadipocytes by slow-speed centrifugation and washed with KRBH solution by repeated centrifugation. Prior to all metabolic studies, cell viability was evaluated by trypan or methylene blue exclusion and cells were counted using an improved Neubauer hemacytometer (American Scientific Products). For FFA assay, one-hundred-microliter aliquots of adipocytes were then transferred to 24-well plates and incubated with isoproterenol (1 µM) for 2 h (10). FFA and glycerol levels in the medium were measured with a colorimetric kit by using FFA and Glycerol kit (Abcam, UK), respectively, and normalized to cell density.
Microsomal enzymatic activity assays in adipose tissue. The adipose microsomal pellet was obtained and H6PDH enzyme activity was carried out by spectrophotometric measurement of NADPH production in the presence of G6P and NADP using absorbance at 340 nm per our previously reports (47, 15). One hundred µg of protein from adipose microsomes was incubated with 0.5-5 mM G6P, 1-5 mM NADP, and 100 mM glycine buffer solution at 22 °C for 0-10 min. The adipose microsomes were permeabilized with 1% Trition-100 to allow the free access of the cofactor to the intraluminal enzyme. Proteins were transferred to nitrocellulose membranes. Membranes were washed and incubated with the appropriate secondary antibody. Protein bands were visualized using enhanced chemiluminescence (Amersham) and exposure to Hyperfilm ECL x-ray film.
Statistical Analysis. The data shown represent means ± SEM for all of the determinations.
Data were compared using an unpaired Student's t-tests. To compare multiple groups, oneway analysis of variance (ANOVA) was used. When ANOVA revealed significant differences, then group comparisons were performed using the Newman-Keul's post-hoc test. A P value < 0.05 was considered statistically significant.
RESULTS

Phenotypic characterization of transgenic aP2/H6PDH mice.
To determine whether overexpression of H6PDH has an effect on energy homeostasis, we first compared body weight, food intake, and white adipose fat pad weight between the aP2-H6PDH transgenic mice (aP2/H6PDH Tg mice) and their nontransgenic littermates controls (WT) in 20-week-old mice. As shown in Fig. 1A , aP2/H6PDH Tg mice showed no significant difference in body weight compared with WT littermates when animals were maintained on a normal chow diet. Similarly, there was no significant difference in food intake between the aP2/H6PDH Tg mice and WT littermates (data not shown). However, adipose fat pad weight was significantly increased in epididymal fat (P < 0.05) and subcutaneous fat pad (P < 0.05) with a 37% elevation of total fat mass (P < 0.05) in aP2/H6PDH Tg mice compared to age-matched WT control levels, respectively (Fig. 1B) . Consistent with these observations, morphometric analysis of adipose tissue showed significant increase in adipocyte cell number within the fat tissue in the aP2/H6PDH mice (P < 0.05; Fig. 1C ).
Histological analysis showed that adipocytes size from the aP2/H6PDH mice was increased by 15% compares with WT controls (P < 0.05, Fig. 1D and 1E). These data show that aP2/H6PDH Tg mice develop regional fat accumulation and mild obesity. 
Transgenic aP2-H6PDH mice had enhanced endogenous adipose GC production in adipose tissue. To determine if overexpression of H6PDH modulates glucocorticoid (GC)
action in vivo, we measured adipose 11βHSD1 activity, corticosterone levels, and GC receptor (GR) expression in aP2-H6PDH Tg mice. As shown in Fig. 3A , 11ß-HSD1 reductase activity was increased by 1.9-fold in epididymal fat and 1.5-fold in mesenteric fat (P < 0.01; Fig. 3A ) and 1.4-fold in subcutaneous fat in aP2-H6PDH mice compared to controls, respectively. Consistent with these observations, epididymal and mesenteric and subcutaneous adipose 11ß-HSD1 mRNA expression was increased by 3.0-and 1.7-and 1.5 fold in aP2-H6PDH mice compared to their respective controls (P < 0.01; Fig. 3B ).
Similarly, adipose tissue corticosterone concentrations were significantly elevated by 42% (P < 0.01) in epididymal fat and by 38% (P < 0.01) in subcutaneous fat and by 16% (P < 0.05) in mesenteric fat in aP2-H6PDH mice compared to their respective controls ( Fig.   3C ), reflecting increased local corticosterone production. However, there was no significant difference in plasma corticosterone levels between aP2-H6PDH mice and WT controls (Fig. 3D) . In contrast, real-time RT-PCR analysis showed that GR mRNA expression were elevated by 3.6-fold epididymal fat (P < 0.01), 1.9-fold in mesenteric fat (P < 0.001), and a 1.7-fold (P < 0.05) in subcutaneous fat in aP2-H6PDH Tg mice compared to WT control levels (Fig. 3E) , respectively. These data reflect increased adipose glucocorticoid action in aP2-H6PDH Tg mice, despite circulating glucocorticoid levels. In addition, C/EBPα mRNA levels were significantly increased in epididymal fat (3.3-fold; P < 0.01) and subcutaneous fat (2.7-fold; P < 0.01) and mesenteric fat (1.4-fold; P < 0.05) in aP2/H6PDH Tg mice compared to WT controls, respectively (Fig. 3F) .
Moreover, the changes in adipose 11ß-HSD1 production and corticosterone concentrations were positively correlated with C/EBPα mRNA expression in aP-H6PDH Tg mice and WT controls (P < 0.01, respectively).
aP2-H6PDH Tg mice showed impaired glucose tolerance and insulin sensitivity. To further explore the impact of overexpression of adipose H6PDH on glucose homeostasis and insulin sensitivity, we performed glucose and insulin tolerance tests and compared plasma insulin level between the aP2/H6PDH Tg mice and age-matched WT controls. As shown in Fig. 4A , aP2/H6PDH mice in the fasting state were markedly hyperglycemic (155 ± 14 mg/dL) compared with WT controls (120 ± 7.7 mg/dL; P < 0.001). Consistent with plasma glucose elevation, aP2/H6PDH Tg mice showed higher glucose concentrations at all times during the glucose tolerance test. Similarly, the AUC levels of glucose intolerance in the aP2/H6PDH Tg mice were significantly increased compared with WT controls (Fig. 4B ). In the insulin tolerance test, blood glucose concentration at 60, 90, and 120 min were higher in aP2-H6PDH Tg mice in comparison to that observed in WT control mice after i.p. insulin challenge (P < 0.05; Fig. 4C ). In agreement with these observations, fasting insulin levels were elevated in aP2-H6PDH Tg mice compared with that of WT controls (P=0.015548; Fig. 4C ), indicating that the aP2-H6PDH Tg mice exhibited signs of developing insulin resistance.
Transgenic aP2/H6PDH mice had increased circulating FFA levels and lipolysis in adipose tissue. To investigate if the induction of endogenous adipose GC action may
contribute to adipose lipolysis in aP2-H6PDH Tg mice, we measured the plasma free fatty acid (FFA) levels and the expression of key adipose lipolytic enzymes, HSL mRNA and protein expression in adipose tissue. Biochemical analyses showed that aP2/H6PDH Tg mice had elevated plasma FFA levels compared with that of WT controls under both fed and fasted conditions, respectively (P < 0.01) (Fig. 5A ). Real-time RT-PCR analysis demonstrated that epididymal fat HSL mRNA level was increased by 2.1-fold (P < 0.01) in the fasting and 1.5-fold (P < 0.05) in fed condition compare to WT controls, respectively (Fig. 5B) . Parallel to the increase in plasma FFA and adipose HSL mRNA expression, Western blot analysis confirmed that epididymal fat HSL protein levels were increased by 2.3-fold in fasting state and 1.6-fold in the fed state in aP2-H6PDH Tg mice (P < 0.01 vs. respective WT mice) ( Fig. 5C and 5D ). Consistent with elevated HSL expression, Ser 660 phosphorylation of epididymal adipose HSL was induced by 3.3-fold and 2-fold (P < 0.01) in the aP2-H6PDH mice compared to WT animals under both fasted and fed conditions ( Fig. 5C and 5D ), respectively. Similarly, the epididymal fat ATGL protein levels were increased by 3-fold in fasting state (Fig. 6A ) and 1.9-fold in the fed state (Fig. 6B ) in aP2-H6PDH Tg mice (P < 0.01 vs. respective WT mice). These data suggesting that activation of adipose lipolysis may contribute to elevated circulating FFA levels in the aP2-H6PDH Tg mice.
aP2/H6PDH mice increase FFA and glycerol release levels in isolated adipocytes. To further determine if elevated circulating FFA levels caused by H6PDH overexpression could be observed in an in vitro setting, we measured FFA and glycerol released levels in the media in basal and isoproterenol-treated adipocytes from aP2/H6PDH mice compared with that of WT controls. Trypan blue exclusion assay revealed that the trypan-blue uptake of the isolated adipocyte are comparable (2.8 ± 1.2% in aP2/H6PDH mice compared with 2.7 ± 1.1 % in WT controls) ( Fig. 7A ; P > 0.05) and over 97% cells are viable. As shown in Fig. 7B and 7C, basal released levels of FFA and glycerol in the media are higher in isolated adipocytes from aP2/H6PDH mice compared with that of WT, respectively. Treatment of cells with isoproterenol induced a significant increase in FFA release levels in isolated adipocytes from WT mice, but even stronger response to isoproterenol stimulation was observed in cells from aP2/H6PDH (Fig. 7B) . Similarly, isoproterenol stimulated glycerol release levels in these cells from WT mice reached only 60% of the levels seen in isolated adipocytes from aP2/H6PDH mice (Fig. 7C ). These data indicate that aP2/H6PDH mice directly induced adipose FFA and glycerol release.
DISCUSSION
We demonstrated that aP2-H6PDH transgenic mice exhibited increased 11β-HSD1 activity and expression in response to elevated H6PDH expression in adipose tissue. We observed that corticosterone levels were increased in adipose tissue of aP2-H6PDH Tg mice that was accompanied by the induction of adipose microsomal 11ß-HSD1 reductase activity, indicating increased conversion of corticosterone from 11-DHC.
Importantly, we found that aP2-H6PDH Tg mice showed fasting hyperglycemia and glucose intolerance along with elevated levels of the fasting plasma insulin and FFA, activity that is implicated to contribute to T2MD. The adipose H6PDH mRNA levels in aP2-H6PDH Tg mice are comparable to or slightly higher than that in adipose tissue of obese rodents and diabetic humans, suggesting that the phenotypic changes found in aP2-H6PDH Tg mice are physiologically and pathologically relevant. However, the aP2 promoter is not exclusively fat-specific; it is also reported to be expressed in macrophages and brains (27, 4), supporting the possibility that non-adipocyte expression of H6PDH may have contributed to their observed phenotype, although H6PDH Tg mice did not have altered hypothalamic H6PDH mRNA levels. Thus it is unlikely that non-adipocyte H6PDH gene expression accounts for the phenotype observed with H6PDH Tg mice.
Induction of H6PDH expression could enhance intracellular NADPH availability that drives 11ß-HSD1 activity and consequently intracellular GC production that would lead to insulin resistance and hyperglycemia (47, 45, 25). In accordance with this concept, adipose 11β-HSD1 reductase activity was impaired in H6PDH knockout mice through unavailability of local NADPH and these mutant mice exhibited an insulin-sensitive phenotype and fasting hypoglycemia (16) . These data support the notion that the elevated H6PDH expression in our study is sufficient to increase local GC production in adipose tissues and associated fasting hyperglycemia and adverse metabolic phenotypes, as observed in the aP2-H6PDH Tg mice through induction of 11ß-HSD1 activity. The findings in aP2-H6PDH Tg mice endorse transgenic overexpression of fat 11ß-HSD1 that generates the metabolic syndrome through elevated adipose GC regeneration (29, 30).
Thus, the aP2-H6PDH Tg mouse are an ideal model for studying the potential impact of elevated H6PDH in adipose 11β-HSD1 linked to the pathogenesis of metabolic syndrome.
It is well known that GCs are also capable of promoting adipose tissue differentiation, particularly in the central adipose regions and their excess in circulation induces visceral obesity, insulin resistance and T2MD, which are observed in patients with
Cushing's syndrome (28, 19) . Similarly, the aP2-11ß-HSD1 mice show increased activity of adipose GCs and share some phenotypes to that observed in Cushing's syndrome. It is noteworthy that the aP2-H6PDH Tg mice showed mild epididymal fat and subcutaneous fat accumulation with a small amount of weight gain without significant abdominal obesity in response to elevated local GC production in the abdominal region that differs from that seen in aP2-11ß-HSD1 mice that develop pronounced visceral obesity (29).
Importantly, mesenteric fat GC concentrations are mildly increased, but not to the degree that is observed in epididymal and subcutaneous fat in aP2-H6PDH Tg mice. In contrast, aP2-11ß-HSD1 mice have more mesenteric fat mass with higher corticosterone production in mesenteric mass than seen in epididymal fat and subcutaneous fat. Histological analysis showed that the average adipose cell size from aP2-H6PDH Tg was relatively large that is similar, but less marked than observed in aP2-11ß-HSD1 Tg mice (29). These data could explain the difference in obese phenotype between mice overexpressing 11β-HSD1 and Data are mean ± SEM of 7-8 mice/group. *P < 0.01 vs. WT control mice; **P < 0.05 vs.
WT control mice. 
